Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/2623
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAlcaide, Julia-
dc.contributor.authorDelgado, Mayte-
dc.contributor.authorLegerén, Marta-
dc.contributor.authorJurado, José Miguel-
dc.contributor.authorBlancas, Isabel-
dc.contributor.authorPereda, Teresa-
dc.contributor.authorLópez, Jorge-
dc.contributor.authorGarrido, Margarita-
dc.contributor.authorSánchez, María J-
dc.contributor.authorGarcía, José L-
dc.contributor.authorRueda, Antonio-
dc.date.accessioned2017-05-02T11:51:13Z-
dc.date.available2017-05-02T11:51:13Z-
dc.date.issued2016-11-
dc.identifier.citationAlcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, et al. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett. 2016 ; 12(5):3127-3134es_ES
dc.identifier.issn1792-1074 (Online)es_ES
dc.identifier.issn1792-1074 (Print)es_ES
dc.identifier.otherPMC5103908es_ES
dc.identifier.urihttp://hdl.handle.net/10668/2623-
dc.descriptionJournal Article;es_ES
dc.description.abstractAflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine-oxaliplatin-based chemotherapy with bevacizumab. A doublet with irinotecan combined with aflibercept was administered until progression of disease. The majority of patients received a greater number of aflibercept cycles than the median reported in the VELOUR study (12 vs. 7 cycles), with manageable and reversible toxicity. The most frequent adverse events observed were diarrhoea, neutropenia, fatigue, proteinuria and hypertension. Most cases obtained a progression-free survival greater than the median reported in the VELOUR study (11 vs. 6.9 months) and, in a subgroup of patients previously treated with bevacizumab, and a median survival time of ~47 months was reached from the initial treatment of the disease. The present study contrasts the efficacy and safety results obtained from the pivotal VELOUR trial, and confirms that aflibercept, used in routine clinical practice outside of the clinical trial environment, is active and well-tolerated following bevacizumab treatment.es_ES
dc.description.sponsorshipMedical writing assistance, supported financially by Sanofi Spain (Barcelona, Spain).es_ES
dc.language.isoenes_ES
dc.publisherSpandidos Publicationses_ES
dc.relation.ispartofOncology Letterses_ES
dc.subjectMetastatic colorectal canceres_ES
dc.subjectAfliberceptes_ES
dc.subjectAngiogenesises_ES
dc.subjectTargeted therapyes_ES
dc.subjectVEGFes_ES
dc.subjectVEGFRes_ES
dc.subjectCamptotecinaes_ES
dc.subjectNeoplasias colorrectaleses_ES
dc.subjectEnsayos de Uso compasivoes_ES
dc.subjectSupervivencia sin enfermedades_ES
dc.subjectHumanoses_ES
dc.subjectHipertensiónes_ES
dc.subjectMutaciónes_ES
dc.subjectCompuestos organoplatinoses_ES
dc.subjectPoliéstereses_ES
dc.subjectProteinuriaes_ES
dc.subjectProteínas recombinantes de fusiónes_ES
dc.subjectReceptores de Factores de crecimiento endotelial vasculares_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Alkaloids::Camptothecines_ES
dc.subject.meshMedical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasmses_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Therapies, Investigational::Compassionate Use Trialses_ES
dc.subject.meshMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survivales_ES
dc.subject.meshMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humanses_ES
dc.subject.meshMedical Subject Headings::Diseases::Cardiovascular Diseases::Vascular Diseases::Hypertensiones_ES
dc.subject.meshMedical Subject Headings::Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutationes_ES
dc.subject.meshMedical Subject Headings::Diseases::Hemic and Lymphatic Diseases::Hematologic Diseases::Leukocyte Disorders::Leukopenia::Agranulocytosis::Neutropeniaes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Organic Chemicals::Organometallic Compounds::Organoplatinum Compoundses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Macromolecular Substances::Polymers::Polyesterses_ES
dc.subject.meshMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Urological Manifestations::Proteinuriaes_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Recombinant Proteins::Recombinant Fusion Proteinses_ES
dc.subject.meshMedical Subject Headings::Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Phosphotransferases::Phosphotransferases (Alcohol Group Acceptor)::Protein Kinases::Protein-Tyrosine Kinases::Receptor Protein-Tyrosine Kinases::Receptors, Vascular Endothelial Growth Factores_ES
dc.titleEfficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases.es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.versionYeses_ES
dc.identifier.pmid27899972es_ES
dc.rights.accessRightsAcceso abiertoes_ES
dc.identifier.doi10.3892/ol.2016.5068es_ES
dc.type.versioninfo:eu-repo/semantics/publishedes_ES
dc.relation.publisherversionhttps://www.spandidos-publications.com/ol/12/5/3127es_ES
dc.contributor.authoraffiliation[Alcaide,J; Rueda,A] Oncology Department, Costa del Sol Hospital, Marbella, Málaga, Spain. [Delgado,M; Legerén,M; Jurado,JM; Blancas,I; Sánchez,MJ; García,JL] Oncology Department, San Cecilio Clinical Hospital, Granada, Andalucía, Spain. [Pereda,T; López,J] Pathology Department, Costa del Sol Hospital, Marbella, Málaga, Spain. [Garrido,M] Pharmacy and Nutrition Department, Costa del Sol Hospital, Marbella, Málaga, Spain.es_ES
dc.type.subtypeArtículo originales_ES
Appears in Collections:01- Artículos - APES Costa del Sol
01- Artículos - Complejo Hospitalario Universitario de Granada

Files in This Item:
File Description SizeFormat 
Alcaide_EfficacyAndSafetyOfAflibercept.pdfArtículo publicado1,04 MBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons